Tekmira to Merge with Private HBV Drug Developer OnCore | GenomeWeb

NEW YORK (GenomeWeb) – Canadian RNAi drug developer Tekmira Pharmaceuticals has announced that it has agreed to merge with US-based OnCore Biopharma to create a new company focused on an oral cure for hepatitis B virus infection.

As a result of the transaction, which is expected to close in the first half of this year, Tekmira will shift away from being a pure-play RNAi drug firm aiming to use the gene-silencing technology to treat multiple different diseases to a company focused on developing multiple technologies against a single indication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.